Insmed CEO Will Lewis on Rare Disease Gene Therapy, Burn Supri Launch, and Pipeline

Burn Supri Launch and Q4 Outlook

• 🚀 Burn Supri has shown strong early performance with approximately 200 patients on the drug within its first six weeks.
• 🎯 Q4 will be a crucial test to determine the launch curve's shape, with optimism for continued uptake.
• 💡 Potential catalysts for Burn Supri include inclusion in US treatment guidelines, which have recently been updated to recommend its use.

Addressing Bronchiectasis and Market Expansion

• 🔑 Insmed is the first company to develop an impactful therapy for bronchiectasis, a condition recognized since 1819.
• 📈 The company aims to expand prescribing beyond centers of excellence to nearly 30,000 pulmonologists in the US.
• 🌍 Insmed's addressable market is projected to grow from 250,000-280,000 patients to over 2.5 million by the end of the decade with pipeline success.

Pipeline and Future Catalysts

• 🔬 Upcoming data from the CRS without nasal polyps trial will be presented at the JP Morgan Healthcare Conference in January.
• ⚠️ The company is also awaiting data for HS hydrainitis suppurativa in the first part of next year.
• 📈 TPIP is a drug targeting pulmonary hypertension with four indications set to begin Phase 3 trials next year.

Financial Health and Future Growth

• 💰 Insmed has a strong cash position of $1.7 billion, providing a significant runway for upcoming trials.
• 🚀 The company anticipates kicking off as many as a dozen Phase 3 trials next year, indicating a period of intense clinical development.
• ✅ Future growth is expected to be driven by increasing revenue from Burn Supri and continued performance of their first drug, Arikace.